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Introduction
Angiogenesis is an absolute requirement in normal
tissues for embryogenesis, skeletal growth, and
reproductive functions. It is also associated with
several pathologic conditions such as tumor growth
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Background: Vascular endothelial growth factor (VEGF) is a key regulator of physiologic as well as pathologic
angiogenesis. The response of VEGF to endothelial cell mitogenesis and survival, as well as angiogenesis and
microvascular permeability, is mainly mediated through its receptor-2, VEGFR2 (kinase domain receptor or fetal liver
kinase-1, KDR or Flk-1). This study aimed to detect the expression of VEGFR2 in various forms of thyroid tumors.
In addition, the expression of Flk-2 (receptor for Flt-3) and c-Kit (receptor for steel locus factor), which shows strong
similarity to Flk-1, was also examined in thyroid tumors.
Methods: RT-PCR analyses of c-Kit and immunohistochemical staining of c-Kit, Flk-1, and Flk-2 were performed in
archived samples of 18 papillary thyroid carcinoma (PTC), 9 follicular thyroid carcinoma (FTC), 12 follicular adenoma
(FA), and 7 nodular goiter (NG) samples. The data were correlated to clinicopathologic features.
Results: By RT-PCR analyses, c-Kit expression was detected in 22% (4/18) of PTC, 22% (2/9) of FTC, 25% (3/12)
of FA, and 57% (4/7) of NG samples. However, positive immunostaining signals of c-Kit were only observed in 17%
(3/18) of PTC samples, and not in the others. Similarly, Flk-1 expression was only detected by immunohistochemistry
in 67% (12/18) of PTC and 43% (3/7) of NG samples, and not in the others. Interestingly, the expression of
Flk-2 was found in 89% (16/18) of PTC, 89% (8/9) of FTC, 75% (9/12) of FA, and 29% (2/7) of NG samples. An
inverse relationship of thyroid cancer size with Flk-2 expression was found.
Conclusion: Flk-2 expression was detected in various forms of thyroid tumors and increased Flk-2 expression was
correlated with thyroid tumors with increased transforming activity, suggesting that Flk-2 is involved in pathogenic
development of thyroid malignancy. Similarly, Flk-1 expression was also found in some thyroid tumors, while the
expression of c-Kit-mediated pathways may not play a major role in thyroid tumorigenesis. [J Chin Med Assoc 2006;
69(2):74–79]
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and its metastases. The process of branching out
of new blood vessels from preexisting vasculature
is essential for thyroid organogenesis.1 It has also
been found in the thyroid in the disease process of
goiter, Graves disease, thyroiditis, and neoplastic
transformation.2
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Angiogenic tyrosine kinase receptors in thyroid tumors
Vascular endothelial growth factor (VEGF) is a
key regulator of physiologic as well as pathologic
angiogenesis. The response of VEGF is mediated
through its receptor-1 and -2, VEGFR1 (Flt-1 or
Fms-related tyrosine kinase 1) and VEGFR2 (KDR
or Flk-1). In general, VEGFR2 is the major mediator
of endothelial cell mitogenesis and survival, as well
as angiogenesis and microvascular permeability,
whereas VEGFR1 acts as a negative regulator to
sequester VEGF and prevents its interaction with
VEGFR2. The action of VEGF and its receptors has
been implicated in the growth and metastasis of
thyroid tumors.3–8 Increased expression of VEGF,
VEGFc, KDR/Flk-1, and Tek was found in human
thyroid tumor and higher VEGF expression was
correlated with tumor size in adults.6 Among them,
VEGFc and VEGFR3 mRNA were found in benign
thyroid tumors as well as thyroid carcinoma,4 and
the expression of VEGFc may contribute to
intrathyroid spread of tumor cells.3,5 Overexpression
of tyrosine kinase Flt and c-Met was associated
with increased recurrence of thyroid cancer.3 The
expression of VEGF was found to be higher in
differentiated thyroid cancer tissue.7 Moreover,
Katoh et al8 found significantly increased expression
of VEGF in undifferentiated carcinoma cells near
necrotic foci where the supply of oxygen was
reduced. By immunohistochemistry, Klein et al9 also
found higher expression of VEGF in metastatic
thyroid tumors than in nonmetastatic tumors. The
involvement of VEGF in angiogenesis and growth
of thyroid tumors was further supported by the
observation that the inhibition of VEGF secretion by
phenylacetate10 or VEGF antisense oligonucleotides11
was correlated with growth inhibition of thyroid
cancer cells. These results together suggest that
angiogenesis plays an important role in the growth
and metastasis of thyroid cancer. Although
angiogenesis is a prerequisite in the pathogenic
development of thyroid tumors, many molecules that
have been implicated as positive regulators of
angiogenesis were found to be weakly or negatively
expressed in subsets of thyroid tumors. These
angiogenic factors include VEGF, VEGFc, VEGFR3,
KDR/Flk-1 and Tek,6 hepatocyte growth factor,12
and metalloproteinase-9.13 To explore other factors
that may be associated with angiogenesis and
metastasis of thyroid tumors, this study aimed to
examine the expression of c-Kit (CD117), Flk-1
(VEGFR2 or KDR), and Flk-2 (Flt-3, STK1, or
CD135), and to determine whether they work
cooperatively to promote vascular formation in thyroid
tumors.
Methods
Patients
Thyroid tumor and adjacent tissues were obtained
from patients who underwent thyroid surgery at the
Taipei Veterans General Hospital. Informed consent
was obtained from each patient. All the carcinoma
patients underwent total thyroidectomy, while others
had lobectomy or subtotal thyroidectomy. The
operation was performed by a single surgeon and the
specimens were snap frozen immediately after resection
and stored in liquid nitrogen until use. Normal thyroid
specimens were obtained from the grossly normal part
of the thyroid and were also histologically verified.
The patient group consisted of 18 histologically
confirmed papillary thyroid carcinomas (PTCs), 9
follicular thyroid carcinomas (FTCs), 12 follicular
adenomas (FAs), and 7 nodular goiters (NGs). Among
them, 5 were males and 41 were females with age
ranging from 15 to 81 years. The cancer group (PTC
and FTC) versus benign tumor group (FA and NG)
were compared by Chi-square test or independent
t-test. Differences were considered statistically
significant when the p value was less than 0.05.
Immunohistochemistry
Sections 5 +m thick were prepared from the archived
wax blocks of thyroid tumor and their nontumor
counterpart tissues, and mounted on silane-coated
slides and dried at 56$C for 2 hours. After dewaxing,
sections were pretreated by microwave at 800 W for 20
minutes in 10 mM citrate buffer (pH 6.0) for antigen
retrieval. The sections were then incubated with
polyclonal antibodies against c-Kit (dilution 1:50;
MBL, Japan), Flk-1 (dilution 1:100; Santa Cruz
Biotechnology, CA, USA), and Flk-2 (dilution 1:100;
Santa Cruz Biotechnology), respectively, at 4$C for 16
hours. In a sequential order, the tissue slides were
incubated with a nonspecific blocker (10% nonimmune
rabbit serum; Zymed, San Francisco, CA, USA) for 10
minutes, biotinylated with universal immunoglobulin
G (IgG) for 10 minutes, streptavidin peroxidase
conjugate for 10 minutes, AEC substrate chromogen
for 5 minutes, and then counterstained with hematoxylin
for 5 minutes. Pre-immune rabbit IgG was used as the
negative control. Slides were reviewed based on tumor
cells in 5 random = 20 microscopic fields by the same
pathologist (A.H.Y.). The stains were graded according
to the percentage of cancer cells showing positive
signals: “+” represents a positive finding in less than 25%
of tumor cells; “++” represents a positive finding in 25–
50% of tumor cells; “+++” represents a positive finding
in 50–75% of tumor cells; “++++” represents a positive
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finding in more than 75% of tumor cells; “–/+”
represents a faint stain between a positive and negative
finding of tumor cells.
Isolation of RNA and RT-PCR
Total RNA was isolated from 50 to 100 mg of frozen
tissues in 1 mL of TRIZOL reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
recommendation. One microgram of total RNA was
converted to cDNA by MMLV-reverse transcriptase
(Roche, Penzberg, Germany) in 20 +L of reaction
mixture containing 50 mmol/L Tris-HCl (pH 8.3),
75 mmol/L KCl, 3 mmol/L MgCl2, 10 mmol/L
DTT, and 1 mmol/L dNTP with 0.625 +g random
primers following the manufacturer’s instructions.
Polymerase chain reaction (PCR) was carried out in
a 10-+L reaction mixture containing 10 mmol/L
Tris-HCl (pH 8.3), 50 mmol/L KCl, 3 mmol/L
MgCl2, 0.01% (w/v) gelatin, 2 mmol/L dNTP,
0.1 +g/mL of each primer, 1 +L of properly diluted
cDNA, and 2.5 units Taq DNA polymerase,
respectively. Forty cycles of PCR (94$C for 15 seconds,
53$C for 30 seconds, and 72$C for 40 seconds) were
performed with primers specific for c-Kit (sense primer,
5'-GCT GCC AAG TCT CTG TGA ATA-3' and
antisense primer 5'-ACC ACA GTC CAT GCC ATC
AC-3' ; GenBank accession no. BC004558) transcripts,
and 25 cycles of PCR (94$C for 30 seconds, 55$C for
30 seconds, and 72$C for 1 minute) were performed
with primers specific for GAPDH (sense primer,
5'-TCC ACC ACC CTG TTG CTG TA-3' and
antisense primer, 5' -GGC ACG GTT GAA TGT AAG
GCT-3' ; GenBank accession no. NM-002046)
transcripts. PCR products were separated by agarose
gel electrophoresis and examined under UV after
ethidium bromide staining.
Results
Using immunohistochemistry, we examined the
expression of c-Kit, Flk-1, and Flk-2 in thyroid tumors
from 46 patients. Table 1 shows the clinical information
of the 46 patients and the relation to the expression of
Table 1. Clinical information for the 46 patients and the relation to the expression of c-Kit, Flk-1, and Flk-2
Diagnosis Total PTC FTC FA NG p value
n = 46 n = 18 n = 9 n = 12 n = 7 (PTC+FTC vs
 FA+NG)
Male/Female 5/41 0/18 0/9 4/8 1/6 0.311*
Age, yr, 42.7 ( 16.0 45.4 ( 15.2 36.4 ( 15.2 41.8 ( 15.5 45.3 ( 21.0 0.932†
mean ( SD (range) (15–81) (25–81) (23–71) (15–63) (21–72)
Flk-1
– 31 6 9 12 4
–/+ 10 7 0 0 3
+ 5 5 0 0 0 0.067*
Flk-2
– 11 2 1 3 5
–/+ 6 1 1 3 1
+ 19 6 6 6 1
++ 8 7 1 0 0
+++ 2 2 0 0 0 0.005*
c-Kit
– 43 15 9 12 7
–/+ 3 3 0 0 0 0.257*
Tumor size, n = 27
cm 2.8 ( 1.6 2.4 ( 1.4 3.6 ( 1.7
* PTC + FTC versus FA + NG compared by Chi-square test. †PTC + FTC versus FA + NG compared by independent t-test. p < 0.05 is considered
statistically significant. PTC = papillary thyroid carcinoma; FTC = follicular thyroid carcinoma; FA = follicular adenoma; NG = nodular goiter; n = case
number.
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c-Kit, Flk-1, and Flk-2. Figure 1 shows the positive
immunohistochemical staining of Flk-2 in PTC.
Intense cytoplasmic staining was observed in tumor
cells. Similarly, positive cytoplasmic staining was
observed in tumor cells of FTC (Figure 2). Among the
46 samples examined, positive signals of Flk-2
expression were found in 89% (16/18) of PTC, 89%
(8/9) of FTC, 75% (9/12) of FA, and 29% (2/7) of
NG samples. Figure 3 summarizes the profile of
Flk-2 expression in various forms of thyroid tumors.
The Flk-2 expression showed a trend of inverse
relationship to thyroid cancer size with a p value of
0.182 (Figure 4). The expression of c-Kit was examined
with both immunostaining and RT-PCR analyses,
while the expressions of Flk-1 and Flk-2 were detected
by immunostaining alone because it had better
expression. By RT-PCR analysis, we detected c-Kit
expression in 22% (4/18) of PTC, 22% (2/9) of FTC,
25% (3/12) of FA, and 57% (4/7) of NG samples.
However, positive immunocytostaining signals of
c-Kit were only observed in 17% (3/18) of PTC
samples, and not in the others. Similarly, Flk-1
expression was only detected by immunohistochemistry
in 67% (12/18) of PTC and 43% (3/7) of NG
samples, and not in the others.
Discussion
In the current study, we examined the expression of
c-Kit, Flk-1, and Flk-2 in human thyroid tumors. c-Kit
and Flk-2/Flt-3 are cytokine tyrosine kinase receptors
that are expressed and function in early human
hematopoiesis. Through its ability to promote ex vivo
Figure 4. The relationship between the differentiated thyroid
cancer sizes (18 of papillary cancer plus 9 of follicular cancer) and
its Flk-2 expression.
Figure 1. Papillary thyroid carcinoma with control (A) and positive
expression of Flk-2 (B).
Figure 2. Follicular thyroid carcinoma with control (A) and positive
expression of Flk-2 (B).
Figure 3. Flk-2 expression in thyroid tumors. PTC = papillary thyroid
carcinoma (n = 18); FTC = follicular thyroid carcinoma (n = 9);
FA = follicular adenoma (n = 12); NG = nodular goiter (n = 7).
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expansion and onco-retroviral transduction of human
hematopoietic progenitors, the Flk-2/Flt-3 ligand has
emerged as a key stimulator of human hematopoietic
stem cells,14 which are critical for angiogenesis.15
Flk-1, also known as VEGFR2, is also essential for the
development of hematopoietic stem cells in the embryo.
Although c-Kit, Flk-1, and Flk-2 are important factors
involved in both physiologic and pathologic
angiogenesis, only Flk-1 has been shown to express in
human thyroid cancers.6 Using immunohistochemistry,
we have shown in this study that all 3 were expressed
in human thyroid cancers.
Flk-2/Flt-3 is a marker in hematopoietic stem cell
differentiation.16 Aberrant expression and activating
mutations of Flk-2 have been described and linked to
poor prognosis in acute myeloid leukemia, although
it can be inhibited by bis(1H-2-indoolyl)-1-
methanones.17 Zeigler et al18 have shown that stem
cells expressing Flk-2 have a lower percentage of cells
that remain at G0 as compared with the cells that do
not express Flk-2, suggesting that Flk-2 may promote
cells into active cycling status. In this study, Flk-2 is
most frequently expressed in thyroid tumors, as
compared with Flk-1 and c-Kit. The expression of
Flk-2 was widely detected in both PTC and FTC, and
to a lesser degree, in FA and NG samples (p = 0.005)
(Table 1). These findings suggest that Flk-2 is involved
in the pathogenic development of thyroid cancers.
How the Flk-2 ligand/Flk-2 signal axis contributes
to thyroid tumorigenesis merits further investigation.
Our study also evidenced the expression of Flk-2
expressed in most growing thyroid tumors with
stronger expression in cancer lesions (Figure 3). We
also showed that Flk-2 expression in thyroid tumors
has a trend of inverse relationship to cancer size
(Figure 4). It remains to be determined why this
result is different from the report of Bounone et al6 in
1999 and whether the early rapidly growing thyroid
tumors need more angiogenic activity or more
activated hematopoietic stem cells. This study also
demonstrated that a higher percentage of FTC
expressed Flk-2 as compared with FA (89% vs 75%).
This has always been a dilemma in the differential
diagnosis of FA and FTC. Other than using the
parameters related to the expression of metallopro-
teinase-9,13 nuclear morphometry, and quantitation
of angiogenesis,19 our Flk-2 expressions still seem
difficult to serve as a marker to differentiate FTC
from FA.
c-Kit is a proto-oncogene that expresses mainly in
hematopoietic stem cells and lymphocyte progenitor
cells. c-Kit expression has also been described in a
number of cancers, including uterine carcinosarcoma
and neuroblastomas;20,21 c-Kit expression is associated
with neuroblastomas with a favorable prognosis.20,21
By RT-PCR analysis, we showed that 22–57% of
thyroid tumors of various types expressed c-Kit to
different degrees. Immunohistochemistry also
confirmed the expression of c-Kit in PTC. It is not
clear whether the absence of c-Kit expression in other
types of thyroid tumors by immunohistochemistry is
due to a minute amount of c-Kit protein expression
that is beyond detection. Nevertheless, both RT-PCR
and immunohistochemistry showed that 17–22% of
PTC expressed c-Kit. It warrants further study to
evaluate the relation of c-Kit expression to the prognosis
of PTC in a larger panel of patients. In parallel
experiments, we found positive Flk-1/KDR expression
in 67% (12/18) of PTC and trace signals in 43%
(3/7) of NG samples, and none of the FA and FTC
samples showed any signals. Flk-1/KDR encodes
VEGFR2, which has been implicated in the positive
regulation of VEGF-mediated responses. These results
suggested that the VEGF-mediated signaling pathway
plays an important role in the development of NG and
PTC, but it may play a less important role in the
pathogenesis of FA and FTC.
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